



SURF

Section of **URo**-Oncology Forum

4 & 5 MARCH 2023

Venue : **Connexion Conference
and Event Centre,
Bangsar South, Malaysia**



MINISTRY OF HEALTH MALAYSIA



Malaysian
Oncological
Society



MALAYSIAN UROLOGICAL
ASSOCIATION

CONTENTS



Welcome Messages

Co-organising Chairperson, SURF 2023	3
Co-organising Chairperson, SURF 2023 President, Malaysian Oncological Society	4
President, Malaysian Urological Association	5
Organising Committee / Invited Faculty	6

Daily Programme

4 March 2023	7
5 March 2023	10

Speaker Profiles

International Faculty	12
Local Faculty	16
Speaker Abstracts	23
Information for Speakers and Presenters	31
Exhibition Floor Plan	32
Exhibitor Profiles	33
Congress Information	40
Acknowledgements	42

SURF 2023 Conference Secretariat

Malaysian Urological Association

Unit 1.4 (Suite 2), Level 1, Enterprise 3B, Jalan Inovasi 1, Technology Park Malaysia (TPM)
Lebuhraya Puchong - Sungei Besi, Bukit Jalil 57000 Kuala Lumpur, Malaysia
Email : muc.surf@gmail.com; malaysianurologicalassociation@gmail.com
Website : www.mua.my



Message from

**Co-organising Chairperson, SURF 2023,
Malaysian Oncological Society**

SURF
Section of Uro-Oncology Forum

4 & 5 MARCH 2023

Venue: **Connexion Conference
and Event Centre,
Bangsar South, Malaysia**

Dear colleagues and distinguished guests.

It is my great pleasure to welcome you all to SURF 2023.

In the next two days we gather to share and explore the latest developments and trends in Uro-Oncology.

The long hiatus since our last meeting held in 2018, has made us realize a different realm in medicine. One of isolation, fear, desperation, innovation, togetherness, and finally re-emergence.

The effects of Covid has been far reaching and Uro-Oncology has not been spared. Till today, we are still reeling in many ways due to the pandemic.

In great tragedy is also born great opportunity. We have grown to adapt teleconferencing, and virtual meetings. We have rapidly done away with physical borders due to the absolute need to meet. In this, we are human, and proven to overcome the most challenging of situations.

Uro-Oncology is an area of medicine which is constantly evolving, with new insights and treatments being developed. This conference is a unique opportunity for us to come together and exchange ideas, expertise and knowledge, with the hope to create an interactive environment that fosters collaboration and inspires new ideas, innovation, and collaboration.

We have assembled a faculty of experts, both local and international, who are giants in their own fields.

It is our hope that you leave this conference energized and inspired, with new ideas, and connections to bring back to your own work in the field of Uro-Oncology.

Thank you and Selamat Datang.

Dr J. R Sathiyanthan

Co-organising Chairperson, SURF 2023
Malaysian Urological Association



Message from

**Co-organising Chairperson, SURF 2023
President, Malaysian Oncological Society**

SURF
Section of Uro-Oncology Forum

4 & 5 MARCH 2023

Venue: **Connexion Conference
and Event Centre,
Bangsar South, Malaysia**

As the Co-Organising Chairperson representing Malaysian Oncological Society (MOS) it gives me great pleasure to welcome all participants to the Section of Uro-Oncology Forum (SURF) 2023. Thank you for putting aside your personal time this weekend to be present here to make this event a success.

This collaborative congress of MOS with the Malaysian Urological Association (MUA) was conceptualized to be a once every 2 years event. Our last meeting in 2018 could not be followed up in 2020 due to the restrictions brought about by the Covid pandemic.

SURF is a one-of-a-kind professional meeting where urologists and oncologists participate equally in discussing latest advancements in the field of uro-oncology. Acknowledging the bearing that this meeting has on to the urology and oncology fraternity, it is timely to organize it this year. My heartfelt gratitude to my counterpart as the Co-Organising Chairperson, Mr JR Sathiyananthan for steer-heading this herculean task.

This forum would not be possible without the support of our industry partners. Thank you for your continued support and professional engagement. The industry-sponsored symposiums further add value and valour to our SURF. I humbly request all participants to visit the booths of our sponsor, as a sign of appreciation of their contribution. Our exhibitors are present to answer any questions and enhance our knowledge on the latest developments.

My sincere appreciation goes to the members of the organising and scientific committee who have worked hard to bring about a power-packed and engaging 1.5- day programme to cover as many areas of uro-oncology as possible. The quality of the programme is a proof of this marvelous teamwork.

I would also like to thank the MUA Secretariat, Ms Najatushima Abdul Wahab who has tirelessly worked over the past year to sort out all the logistics required for this Forum.

Do enjoy your time in this conference. Besides learning and attending lectures, let us also make use of this forum as a platform to refresh old ties and forge new ones, as the close working relationship among oncologists and urologists is paramount for the best outcome possible for our patients.

Enjoy the SURF!

Dr Muthukkumaran Thiagarajan

Co-organising Chairperson, SURF 2023
President, Malaysian Oncological Society (MOS)



Message from

**President,
Malaysian Urological Association**

SURF
Section of Uro-Oncology Forum

4 & 5 MARCH 2023

Venue: **Connexion Conference
and Event Centre,
Bangsar South, Malaysia**

Dear friends and colleagues. Assalamualaikum and Salam MADANI to all.

It gives me a great pleasure and honour to welcome all faculty and delegates to the 4th SURF meeting in Kuala Lumpur 2022. SURF is a Uro-Oncology meeting that was first conceptualised by Dr Chua Chong Bing as a platform to bring Malaysian Urologists and Oncologists together to discuss relevant updates in the field.

Since the first three meetings in Kuala Lumpur, SURF has now gained momentum and in 2022, we will see a more flavorful scientific programme with many distinguished international and local speakers. The Malaysian Urological Association would like to welcomes all speakers who have taken time off to join us for this meeting. Your sacrifices are very much appreciated.

This year's meeting is co-organised by the Malaysian Urological Association and the Malaysian Oncological Society. Special thanks should be given to Mr JR Sathiyananthan and Dr Muthukkumaran Thiagarajan as co-organising chairpersons. They are assisted by an excellent team of Malaysian Urologists and Oncologists. Our heartfelt gratitude also goes to Ms Najatushima Abdul Wahab, Executive Secretary of the Malaysian Urological Association for her excellent work and commitment.

It has been our vision to host a SURF meeting every two years. However due to the Covid19 pandemic, we were unable to have it in 2020. We hope to see an increase in participation from our neighboring ASEAN countries in the future. It will be an excellent opportunity not only to share experiences in managing Uro-Oncology challenges across borders but will further enhance good relationships between Oncologists and Urologists in the region.

We are also fortunate for the encouraging support from our industry partners. It is with this collaboration that we hope to have an unforgettable meeting in Kuala Lumpur. I sincerely hope this meeting will not only be a good academic exercise but will also provide opportunities to gain new friends. For our international guests, I hope you will find time to enjoy Malaysian cuisine and some local sights.

Have a wonderful meeting.

Dr Noor Ashani Bin Md. Yusoff

President
Malaysian Urological Association



ORGANISING COMMITTEE

Organising Chairperson

JR Sathiyananthan

Organising Chairperson

Muthukkumaran Thiagarajan

Committees

Adlinda Alip
Arnif Sirimanne
Devindran Manoharan
Hadi Ab Jalil
Marniza Saad

Mohd Najib Aziz
Nur Adila Mokhtar
Omar Fahmy
Sandya Subramaniam
Teh Khai Yeong
William Ong

FACULTY LIST

International Faculty



Australia

Peter Royce
Shankar Siva



Canada

Daniel Heng



Singapore

Edmund Chiong
Ravindran Kanesvaran



United Kingdom

Prasanna Sooriakumaran
Robin Young
Diana Greenfield

Local Faculty



Adlinda Alip
Aldrin Jasper Placidus
Ang Soo Fan
Fong Chin Heng
Lim Wei Sern
Loh Chit Sin
Murali Sundram
Muthukkumaran Thiagarajan
Noor Ashani Md. Yusoff
Ong Teng Aik
Ooi Kai Yun
Rohan Malek
Shazril Imran
Subapriya Suppiah
Suriaraj Karppaya
Teh Khai Yeong
Toh Charng Chee
Vance Koi Yung Chean
Yogendren Letchumanasamy
Zool Hilmi Awang
Zulaikha Binti Rozman

Time	Topic	Speaker
8.00 – 8.30	Registration	
8.30 – 8.45	Welcome speech	Organising Chairpersons

PLENARY 1 : Renal Cancer		
Chairpersons: Devindran Manoharan, <i>Penang General Hospital</i> and Rangasamy Ramachandran, <i>Hospital Sultan Ismail, Johor Bahru</i>		
8.45 – 9.00	Redefining the Role of Nephrectomy in the Era of Immunotherapy in Renal Cell Carcinoma	Toh Charng Chee, <i>Selayang Hospital</i>
9.00 – 9.15	Adjuvant Treatment for Renal Cell Carcinoma: Past, Present and Future	Daniel Heng, <i>Tom Baker Cancer Center, Canada</i>
9.15 – 9.30	Contemporary Role of Metastasis-Directed Therapy in Renal Cell Carcinoma	Shankar Siva <i>Peter MacCallum Cancer Centre, Melbourne, Australia</i>
9.30 – 9.45	Clear Cell Renal Cell Carcinoma: Case Presentation and Discussion	Suriaraj Karrpaya <i>Hospital Queen Elizabeth, Sabah</i>
9.45 – 9.55	Q & A	

9.55 – 10.15	Tea Symposium by Ipsen Pharma Singapore Pte Ltd Implications from Trial to Practice: Real-world Case Sharing on RCC Management	Daniel Heng <i>Tom Baker Cancer Center, Canada</i>
--------------	--	---

10.15 – 10.30 | Tea Break

PLENARY 2 : Renal Cancer		
Chairpersons: Nur Faizah Ab Muin, <i>University Kebangsaan Malaysia Medical Centre</i> and Yeoh Wei Sien, <i>University Malaya Medical Centre</i>		
10.30 – 10.45	Choosing the First Line Treatment for Renal Cell Cancer	Daniel Heng <i>Tom Baker Cancer Center, Canada</i>
10.45 – 11.00	Sequencing Treatment beyond First Line	Ravindran Kanesvaran <i>National Cancer Centre, Singapore</i>
11.00 – 11.15	Non-clear Cell Renal Cell Carcinoma: Case Presentation and Discussion	Zulaikha Binti Rozman <i>University Malaya Medical Centre</i>
11.15 – 11.25	Q & A	

Time	Topic	Speaker
	PLENARY 3 : Prostate Cancer Chairpersons: Sivaneswaran Lechmiannandan, <i>Hospital Raja Perempuan Bainun, Ipoh</i> and Jennifer Leong Siew Mooi, <i>Sunway Medical Centre</i>	
11.30 – 11.45	Focal Therapy for Prostate Cancer- HIFU	Peter Royce <i>The Alfred, Melbourne, Australia</i>
11.45 – 12.00	Prostate SBRT – A Local Experience	Muthukkumaran Thiagarajan <i>Kuala Lumpur Hospital</i>
12.00 – 12.15	Evolution of Robotic Prostatectomy	Loh Chit Sin <i>Gleneagles Hospital Kuala Lumpur</i>
12.15 – 12.25	Q & A	

12.30 – 1300	Lunch Symposium by Johnson & Johnson Sdn Bhd MDT-PacMan: Patient-centric approach in mCSPC	Ravindran Kanesvaran <i>National Cancer Centre, Singapore</i>
--------------	--	--

	PLENARY 4 : MDT for Oligometastatic Prostate Cancer Chairpersons: Sandya Subramaniam, <i>Kuala Lumpur Hospital</i> and J.R Sathiyananthan, <i>Pantai Hospital Kuala Lumpur</i>	
13.30 – 13.45	PSMA PET as a Diagnostic Tool	Yogendren Letchumanasamy <i>Subang Jaya Medical Centre</i>
13.45 – 14.00	Local Therapy in Oligometastasis Prostate Cancer	Prasanna Sooriakumaran <i>UCLH & Cleveland Clinic London</i>
14.00 – 14.15	Role of SBRT for Oligometastasis Prostate Cancer	Shankar Siva <i>Peter MacCallum Cancer Centre, Melbourne, Australia</i>
14.15 – 14.30	Systemic Therapy – When & Why	Adlinda Alip <i>University Malaya Kuala Lumpur</i>
14.30 – 14.45	Case Presentation	Lim Wei Sern <i>Kuala Lumpur Hospital</i>
14.45 – 15.00	Q & A	

15.00 – 15.20	Afternoon Tea Symposium by Astrazence Sdn Bhd Striking Precision Medicine Goals in Advanced Prostate Cancer	Edmund Chiong <i>National University Hospital, Singapore</i>
---------------	---	---

15.20 – 15.45 | Tea Break

Time	Topic	Speaker
	PLENARY 5 : Prostate Cancer Chairpersons: Toh Charng Chee, <i>Selayang Hospital</i> and Hadi Ab Jalil, <i>Hospital Umum Sarawak</i>	
15.45 – 16.00	Biochemical Recurrence Post Primary Treatment	Rohan Malek <i>Selayang Hospital</i>
16.00 – 16.15	Management of Complications of Robotic Radical Prostatectomy	Murali Sundram <i>Sunway Medical Centre</i>
16-15 – 16.45	Triplet Therapy – Are We Ready?	Vance Koi Yung Chean <i>Hospital Wanita & Kanak-Kanak, LIKAS, Sabah</i>
16.45 – 17.00	PARP Inhibitors	Fong Chin Heng <i>Hospital Pulau Pinang</i>
17.00 – 17.15	Lutetium PSMA Therapy for mCRPC	Zool Hilmi Awang <i>Thomson Hospital Kuala Lumpur</i>
17.15 – 17.30	Break	
17.30 – 18.30	Dinner Symposium by Merck Sharpe & Dohme Sdn Bhd Advanced RCC: Treatment Considerations in Local Practice	Ang Soo Fan <i>Penang Adventist Hospital</i>

Time	Topic	Speaker
8.20 – 8.40	Breakfast Symposium by MERCK Sdn Bhd & Pfizer Malaysia A New Horizon for Locally Advanced or Metastatic Urothelial Cancer: From the Perspective of A Urologist	Ong Teng Aik <i>University Malaya Medical Centre</i>

8.40 – 9.00 | Breakfast

PLENARY 6 : Urothelial cancer Chairpersons: Santhi Nadarajan, <i>Gleneagles Hospital Kuala Lumpur</i> and Omar Fahmy, <i>Hospital Pengajar Universiti Putra Malaysia</i>		
9.00 – 9.15	Imaging in UTUC and Its Challenges	Subapriya Suppiah <i>Hospital Pengajar Universiti Putra Malaysia</i>
9.15 – 9.30	Impact of Template Based Lymph Node Dissection on UTUC Treatment Outcome	Murali Sundram <i>Sunway Medical Centre</i>
9.30 – 9.45	Perioperative Systemic Therapy for UTUC	Ooi Kai Yun <i>Hospital Sultan Ismail, Johor Bahru</i>
9.45 – 9.55	Q & A	

9.55 – 10.15	Tea Symposium by Amgen Biopharmaceuticals Malaysia Sdn Bhd Managing Bone Health in the Continuum of Prostate Cancer Chairperson: Ong Teng Aik <i>University Malaya Medical Centre</i>	Edmund Chiong <i>National University Hospital, Singapore</i>
--------------	---	---

10.15 – 10.30 | Tea Break

PLENARY 7 : Urothelial cancer Chairpersons: Tan Guan Hee, <i>Sunway Medical Centre</i> and Muthukkumaran Thiagarajan, <i>Kuala Lumpur Hospital</i>		
10.30 – 10.45	Current Landscape of Immunotherapy in Non-muscle Invasive BC	Ong Teng Aik <i>University Malaya Kuala Lumpur</i>
10.45 – 11.00	Neoadjuvant and Adjuvant Treatment Strategies in Muscle Invasive BC	Aldrin Jasper Placidus <i>Hospital Wanita & Kanak-kanak Sabah</i>
11.00 – 11.15	Laparoscopic and Robotic Radical Cystectomy: The Malaysian Experience	Noor Ashani Md. Yussof <i>Kuala Lumpur Hospital</i>
11.15 – 11.30	Systemic Treatment in Metastatic Urothelial Carcinoma	Shazril Imran <i>Pantai Hospital Sg Petani</i>

Time	Topic	Speaker
	PLENARY 8 : Testicular Cancer Chairpersons: Arnil SiriManne, <i>Prince Court Medical Centre</i> and Mohd Najib Aziz, <i>Selayang Hospital</i>	
11.30 – 11.45	Minimally Invasive Surgery in Advanced Testicular Cancer	Noor Ashani Md. Yusoff <i>Kuala Lumpur Hospital</i>
11.45 – 12.00	Current Management of Refractory Testicular Cancer and Future Directions	Robin Young <i>Weston Park Hospital, Sheffield, United Kingdom</i>
12.00 – 12.15	Approach to the Long-Term Testicular Cancer Survivor	Diana Greenfield <i>Weston Park Hospital, Sheffield, United Kingdom</i>
12.15 – 12.30	MDT Case Discussion	Khai Yeong Teh <i>Hospital Sultanah Bahiyah, Alor Setar</i>
12.30 – 12.40	Q & A	
12.40 – 13.30	Lunch Symposium by Astellas Pharma (M) Sdn Bhd Novel approach in managing advanced urothelial carcinoma	Ravindran Kanesvaran <i>National Cancer Centre, Singapore</i>



Daniel Heng

Medical Oncologist, Clinical Professor
The Tom Baker Cancer Center, Canada



Prof Dr Heng is a Staff Medical Oncologist at the Tom Baker Cancer Center in Calgary, Alberta and a Clinical Professor of Medicine at the University of Calgary. He received his MD from the University of Calgary and completed his internal medicine and medical oncology residencies at the University of British Columbia in Vancouver, BC. He was trained at the BC Cancer Agency in Vancouver, Canada and then completed an Experimental Therapeutics fellowship at the Cleveland Clinic Taussig Cancer Institute. He received a Masters of Public Health from Harvard University. He is the Chair of the International mRCC Database Consortium (IMDC) which has created and validated the IMDC criteria (a.k.a. Heng Criteria) for prognostication in metastatic renal cell carcinoma patients. He is also the Medical Leader for the Clinical Research Unit at the TBCC. He has a keen interest in outcomes, prognostic factors and clinical trials research in metastatic renal cell carcinoma and other genitourinary malignancies. Dr Heng has been involved in many oncology clinical trials from investigator, steering committee and study chair levels. He encourages patients and investigators to always "Think Trials".



Diana Greenfield

Senior Consultant Nurse and MDT Lead for Late Effects
Sheffield Teaching Hospital NHS Foundation Trust



Professor Dr Diana Greenfield, PhD, RN, Cert Ed is Senior Consultant Nurse and MDT Lead for Late Effects at Sheffield Teaching Hospital NHS Foundation Trust. She is also Honorary Professor at both the University of Sheffield and Sheffield Hallam University. Diana leads a multi-disciplinary team for survivors of cancer of childhood, adolescence, and younger adults, including germ cell malignancies.

Diana's late effects team were recognised nationally in the prestigious Health Service Journal/Nursing Times Awards as Cancer Care Team of the Year. Diana was awarded Inspirational Leader of the year by the Yorkshire and Humber NHS Leadership Academy.



Edmund Chiong

Head & Senior Consultant
Department of Urology, National University Hospital

Associate Professor Dr Edmund Chiong graduated with the degrees of Bachelor of Medicine and Surgery from the National University of Singapore (NUS) in 1995. He obtained postgraduate qualifications (Fellow of the Royal College of Surgeons of Edinburgh and Fellow of the Royal College of Surgeons In Ireland) in Surgery and completed his Urology specialist training in Singapore. A/Prof Chiong subsequently completed a two-year clinical fellowship program in Urologic Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas, USA, and was conferred a PhD (NUS). He is also certified by the Society of Urologic Oncology, USA.

His special interests robotic surgery and high-dose rate brachytherapy. He is also a kidney transplant surgeon. Apart from clinical practice, A/Prof Chiong is actively involved in both clinical and laboratory research. His research interests include diagnostic modalities and new therapies for bladder cancer (including immunotherapy, gene therapy and targeted therapy), prostate cancer and other urologic malignancies. He is an investigator in a number of grant-funded, clinical and basic science research projects.

A/Prof Chiong is currently Chairman of the Chapter of Urologists (College of Surgeons), Academy of Medicine, Singapore, is Past President (2016-2018) and current Board of Trustees member of the Singapore Urological Association, and Chairman of the Examinations Committee for Urology and Board member, Residency Advisory Committee / Joint Committee on Specialist Training (JCST), Ministry of Health, Singapore. He is the Cluster Sub-Specialty Lead for Urology and Co-Chair of the Robotic Surgery Program Steering Committee (NRSPSC), at the National University Health System, Singapore. He is also the Deputy Chairman, Scientific Committee, Urological Association of Asia (UAA), a member of the American Urological Association, European Association of Urology and the American Society of Clinical Oncology.

A/Prof Chiong is currently Chairman of the Chapter of Urologists (College of Surgeons), Academy of Medicine, Singapore, is Past President (2016-2018) and current Board of Trustees member of the Singapore Urological Association, and Chairman of the Examinations Committee for Urology and Board member, Residency Advisory Committee / Joint Committee on Specialist Training (JCST), Ministry of Health, Singapore. He is the Cluster Sub-Specialty Lead for Urology and Co-Chair of the Robotic Surgery Program Steering Committee (NRSPSC), at the National University Health System, Singapore. He is also the Deputy Chairman, Scientific Committee, Urological Association of Asia (UAA), a member of the American Urological Association, European Association of Urology and the American Society of Clinical Oncology.



Peter Royce

Director of Urology,
Alfred Health in Melbourne, Australia

Associate Professor Dr Peter Royce is Director of Urology, Alfred Health, Senior Consultant Urologic Surgeon at The Alfred and Cabrini hospitals in Melbourne and Adjunct Clinical Associate Professor, Department of Surgery, Monash University.

He trained in Surgery/Urology in Melbourne and was awarded FRACS (Urology) in 1986. He then completed postgraduate training as Clinical Fellow in Urology at The University of California, Los Angeles USA, and was awarded Fellow American College Surgeons 1993.

He has been in Urology practice since 1987, and is co-founder of the Melbourne Prostate Institute/Brachytherapy Prostate Cancer Clinic at The Alfred, Melbourne.

A/Prof Royce has extensive experience with radical prostatectomy (open and robotic surgery), prostate brachytherapy and high intensity focused ultrasound for the treatment of localised prostate cancer.

He has published articles in peer reviewed Urology journals and presented at numerous scientific meetings and forums, both in Australia and internationally.

He was chairman of the Curriculum Review for the Urological Society of Australia and New Zealand surgical training programme and is a member of Andrology Australia Management Group.



Prasanna Sooriakumaran

Professor of Urology,
Cleveland Clinic Lerner College of Medicine

Professor Prasanna Sooriakumaran, known widely by his initials PS, is Full Professor of Urology at Cleveland Clinic Lerner College of Medicine, Visiting Professor of Urology at the University of Oxford, and Visiting Professor of Urology and Robotic Surgery at the All-India Institute of Medical Sciences Jodhpur. PS is also Lead for Urology at Cleveland Clinic London, the UK site of the second best hospital in the world and works as a Consultant Urological and Robotic Surgeon at Cleveland Clinic London and University College London Hospitals. PS is a world leader in robotic surgery for prostate cancer, and has special interest in surgery for oligo-metastatic prostate cancer which is the focus of his current research.



Ravindran Kanesvaran

Consultant, Division of Medical Oncology
National Cancer Centre Singapore,
Singapore

Associate Prof Dr Ravindran Kanesvaran is a Senior Consultant and Deputy Chair of the Division of Medical Oncology of the National Cancer Centre Singapore. He is also an Associate Professor at Duke-NUS Graduate Medical School. He is actively involved in graduate medical education and is the Past Programme Director of the Medical Oncology Senior Residency Programme. His research interests include genitourinary (GU) oncology and geriatric oncology. He is currently the immediate past President of the Singapore Society of Oncology (SSO) and the Singapore Geriatric Oncology Society. He is the Past President of the International Society of Geriatric Oncology (SIOG). He was also awarded the Singhealth Excellent Service Quality Award in 2018 (Silver) and 2019 (Gold), 2022 (STAR). He is vice-chairman of the Singapore Cancer Society (SCS).



Robin Young

Weston Park Hospital, Sheffield,
United Kingdom

Dr Young completed his specialist medical oncology training in 2014 and then a PhD in sarcoma – specifically in angiosarcoma. His clinical and research interests are in sarcoma, lung cancer, and early phase clinical trials. He is the Teenage & Young Adult medical lead for the Trust, and since 2000, has been the lead oncologist for germ cell tumours.



Shankar Siva

Consultant Radiation Oncologist
LUNG, UROLOGY AND SABR
Peter MacCallum Cancer Centre, Victoria, Australia

Associate Professor Dr Shankar Siva leads the stereotactic body radiotherapy (SABR) service at the Peter MacCallum Cancer Centre. He leads 5 international multicentre trials through the TransTasman Radiation Oncology Group (TROG) with a focus in SABR. He has over 250 publications, with his current research focused on high-tech radiotherapy delivery, in the context immunotherapy combinations, oligometastatic disease, kidney cancer and prostate cancer.

He is the current Cancer Council Victoria Colebatch Fellow.





Adlinda Alip

Clinical Oncologist
University Malaya Medical Centre

Associate Professor Dr Adlinda graduated from Southampton University, UK and completed general medical training before being awarded the MRCP by the Royal College of Physician, UK. She obtained FRCR by the Royal College of Radiologist (Clinical Oncology) UK and awarded certificate of completion (CCT) in Clinical Oncology by General Medical Council UK in 2011. She joined University of Malaya as a Senior Lecturer and Clinical Oncologist in 2012. She is a principal and sub investigator for several ongoing and completed clinical trials. She gives talks and presentations locally and in international meetings. Her main areas of interest include Lung, Breast, Genitourinary and Stereotactic Radiosurgery/Radiotherapy.



Aldrin Jasper Placidus

Clinical Oncologist
Department of Radiotherapy and Oncology,
Sabah Women and Children Hospital

Dr Aldrin is a Clinical Oncologist currently based at the Department of Radiotherapy and Oncology, Sabah Women and Children Hospital. A Sabah native, he obtained his medical degree from University Malaysia Sabah in the year 2010. After fulfilling his duties at the Duchess of Kent Hospital Sandakan, he pursued his interest in oncology and graduated from University Malaya with a Master of Clinical Oncology in 2021.

Devoted to providing optimal cancer care especially in the rural parts of Sabah, Aldrin has been involved in several outreach programs and visiting clinics. He is also a key member of the team which recently establish stereotactic radiosurgery services in Sabah. When taking break from oncology, he pampers himself with music, sports, scuba diving, and loads of adventures.



Ang Soo Fan

Consultant Medical Oncologist
Penang Adventist Hospital

Dr Ang graduated from the University of Malaya in 2001. He obtained his membership of the Royal College of Physicians (United Kingdom) and subsequently practiced as a Medical Specialist in the Department of Internal Medicine at Klang General Hospital.

He underwent advanced specialty training in medical oncology at the National Cancer Centre Singapore (NCCS), and subsequently practiced as a consultant medical oncologist at NCCS.

In addition to general medical oncology, Dr Ang has keen interest in gastrointestinal cancer and liver cancer. Dr Ang is actively involved with multiple international phase III clinical trials, and is also a reviewer of several peer-reviewed journals. He has been actively involved in teaching for oncology trainee and nurses, and also a speaker for many local and international meetings.






Fong Chin Heng

Clinical Oncologist, Hospital Pulau Pinang

Dr Fong Chin Heng obtained his Masters in Clinical Oncology from University of Malaya in 2012. He previously served at Hospital Sultan Ismail, Johor, Malaysia and currently based at Hospital Pulau Pinang Department of Radiotherapy and Oncology



Lim Wei Sern

Medical Officer
Department of Urology,
Hospital Kuala Lumpur

Dr Lim Wei Sern is a year 4 urology trainee, currently working in Hospital Kuala Lumpur. He obtained his undergraduate degree, MBBS in 2011, and subsequently received his Membership Royal College of Surgeon MRCS (Ireland) in 2018. He is currently pursuing a qualification as a Urologist



Loh Chit Sin

Consultant Urologist
Gleneagles Hospital Kuala Lumpur

Dr CS Loh qualified in Medicine with Honours from Liverpool University in the United Kingdom in 1983. He obtained his Fellowship in General Surgery from the Edinburgh Royal College of Surgeon in 1987 and the Fellowship in Urological Surgery in 1996. He was previously Associated Professor in Urology in The University of Malaya and is a past president of the Malaysian Urological Association.

He is active in research and teaching and served as external examiners to The Royal College of Surgeons of Edinburgh and Glasgow, The Academy of Medicine of Singapore and The Malaysian Board of Urology. Dr Loh obtained his Da Vinci console training in 2010 and had done more than 200 cases of robotic prostatectomies.



Murali Sundram

Consultant Urologist
Sunway Medical Centre

Dr Murali graduated with a MBBS in 1984, and went on to do his fellowship in Urology, obtaining an FRCS (Edinburgh) in 1992 and FRCS (Glasgow) in 2014. He has also completed an Adult & Pediatric Urological Fellowship (Adelaide) in 1998.

He currently serves as a Malaysian Board of Urology examiner and Adjunct Professor in MAHSA University College.

His special interests lie in Renal Transplantation, Urethral Reconstruction and Robotic Surgery.





Muthukkumaran Thiagarajan

Clinical Oncologist, Hospital Kuala Lumpur
drmuthuk@gmail.com

Dr Muthukkumaran obtained his Masters in Clinical Oncology from University of Malaya in 2013. He previously served at Sabah Women and Children Hospital and is currently based at Hospital Kuala Lumpur's Department of Radiotherapy and Oncology.

Dr Muthukkumaran has a special interest in pulmonary oncology, genitourinary oncology, neuro oncology (including stereotactic cranial radiosurgery) and paediatric radiation. He is actively involved in both industry-sponsored and investigator-initiated clinical research.

Dr Muthukkumaran is currently the President of the Malaysian Oncological Society (MOS). He is also a national representative to the Federation of Asian Organizations for Radiation Oncology (FARO) and International Atomic Energy Agency (IAEA).



Noor Ashani Md. Yusoff

Consultant Urologist and Head of Department
Hospital Kuala Lumpur, Malaysia

Dr Ashani is the Head of Urology Department, Hospital Kuala Lumpur, Malaysia. He is also an Adjunct Professor at Hospital Pengajar UPM.

He qualified as a General Surgeon in 2002 after completing his Master of Surgery (General) at Universiti Kebangsaan Malaysia (UKM). He continued his training in Urology under the auspices of the Malaysia Board of Urology in collaboration with Ministry of Health Malaysia (MOH) and Malaysia Urological Association (MUA), completing his urology training in 2007. He was conferred Diploma in Fellowship, FRCS (Urology)(Glasgow) in 2014.

His interest lies mainly in minimally invasive surgery, particularly robotic assisted laparoscopic surgery. He started his robotic surgery training since 2004 under the supervision by Dato' Dr. Sahabudin Raja Mohamed, the pioneer of robotic surgery in Malaysia. His robotic surgery training continued at Yonsei Severance Hospital, Seoul, Korea in 2010 under the supervision of Dr. Khoo Hon Rha, the pioneer of robotic surgery in Korea.

To date, he has performed more than 250 cases of Robotic Assisted Laparoscopic surgery, from RAL Radical Prostatectomy to RAL Retroperitoneal Lymph Nodes Dissection. He has proctored more than 50 cases of Robotic Assisted Laparoscopic Surgery and has been invited to give talks related to Robotic Assisted Surgery locally and internationally.





Ong Teng Aik

Consultant Urologist
University Malaya Medical Centre

FRCS (Urology) (UK), FRCSI (Ire), AM (Mal), MS (UM), FEBU, FRCS(Urology), FRCSI, MBBS (UM), MBBS(MAL), MS(Mal)

Prof Dr Ong was born and educated in Kuala Lumpur. He graduated with MBBS from the University of Malaya in 1995. He served for 15 years in various hospitals in Kuala Lumpur (HKL, UHKL), Sabah and Sarawak before joining UMMC in 2010. A/Prof Dr Ong obtained the Fellowship of the Royal College of Surgeons in Ireland in 2000 and the Master of Surgery in 2002. After 2002, he served as a senior lecturer and then Associate Professor in University of Malaysia Sarawak (UNIMAS). He received the Excellence Award in Service from UNIMAS in 2009. A/Prof Dr Ong had most of his urology training in Sarawak General Hospital, Kuching, Sarawak, under senior urologists Dr Teh Guan Chou and Dr Clarence Lei. In the same year, A/Prof Dr Ong won the British Journal of Urology International (BJUI) scholarship to further his training in the United Kingdom. He also published a paper in BJUI on retroperitoneal lymph node dissection with Dr Timothy Christmas, a renowned surgeon of the Charing Cross Hospital, London. For research, A/Prof Dr Ong focuses on uro-oncology.



Ooi Kai Yun

Clinical Oncologist
Hospital Sultan Ismail Hospital Johor

Dr KY Ooi is a clinical oncologist in Sultan Ismail Hospital Johor. She earned her medical degree from University Malaya and completed fellowship in clinical oncology in the Christie Hospital and Royal Marsden Hospital.



Rohan Malek

Senior Consultant Urologist and Head of Department of Urology,
Selayang Hospital, Selangor

Dato' Dr Rohan Malek is the Senior Consultant Urologist and Head of Department of Urology, Selayang Hospital, Selangor, Malaysia. He is appointed as the National Head for Urology, Ministry of Health, Malaysia. Dr Rohan Malek graduated from Monash University, Australia and initially underwent general surgical training and obtained his FRCS from RCS Edinburgh and RCPS Glasgow in 1993. He later underwent Urology specialty training at the Institute of Urology and Nephrology, Kuala Lumpur Hospital from 1993-1996 followed by a 1year Fellowship in the United Kingdom. He obtained the Diploma in Urology from University College London in 1997 and is a Fellow of the European Board of Urology since 2004. He has now been practising as a Consultant Urologist and Renal Transplant surgeon for the past 25 years. As Chairman of the Malaysian Board of Urology, he is also very much involved in the training of Malaysian Urologists. Dr Rohan Malek was the President of the Malaysian Urological Association (MUA) from 2004-2008 and was also the Honorary Treasurer and recent Vice President of MUA. He was the organising Chairman for the 17th Urological Association of Asia (UAA) Congress held in Kuala Lumpur in August 2019 and had been elected as the President of the Urological Association of Asia (UAA) from 2019-2020.



Shazril Imran

Consultant Clinical Oncologist & Radiotherapist
Pantai Hospital Sungai Petani, Kedah, Malaysia

Dr Shazril Imran completed his oncology training at the Christie NHS School of Oncology, Manchester, United Kingdom, obtaining FRCR London in Clinical Oncology in May 2015 and also a Specialty Certificate in Medical Oncology from Federations of Royal College of Physicians of the United Kingdom in October 2015.

He is currently a member of the European Society of Medical Oncology (ESMO), European Society for Radiotherapy & Oncology (ESTRO), Malaysian Oncological Society and Nasopharyngeal Carcinoma Society of Malaysia.

His special interest is breast, lung and head and neck cancers, and germ cell tumours, targeted checkpoint inhibitors and Lung Stereotactic Body Radiotherapy (SBRT) and Head and Neck Intensity Modulated Radiotherapy (IMRT).



Subapriya Suppiah

Consultant Clinical Radiologist and Nuclear Medicine Physician
Universiti Putra Malaysia Teaching Hospital

She is an Associate Professor of Radiology and Nuclear Medicine with a diverse special interest in Nuclear Oncology Imaging, Radionuclide therapy and Mental Health & Cognition neuroimaging. She is a Consultant Clinical Radiologist and Nuclear Medicine Physician at Universiti Putra Malaysia Teaching Hospital. She received her Master in Medicine Radiology training at the University of Malaya. Subsequently, she was awarded fellowships in Nuclear Medicine by the International Atomic Energy Agency (IAEA) Vienna, under training under the supervision of nuclear medicine physician consultants in the UK, Australia, and Malaysia. Dr. Priya is also the Malaysian national counterpart in clinical nuclear medicine for the IAEA under project RAS6091. She is also the Vice President for Nuclear Medicine in College of Radiology, Academy of Medicine Malaysia and also an executive council member of the Malaysian Society of Nuclear Medicine and Molecular Imaging. Her research is in the field of imaging oncological disease, cognitive function, mental health, and behavioural research. She has reviewed for international peer-reviewed journals such as the Lancet and Nuclear Medicine Communications. She has published with top-tiered international and national journals. Furthermore, she has been an invited speaker for various conferences, online seminars, and scientific events in the field of radiology and nuclear medicine. She is currently heading research projects under university as well as Ministry of Higher Education Grants, such as the Fundamental Research Grant Scheme (FRGS) and has several postgraduate students under her supervision. She has been awarded with the High-Performance Researcher Award (Medical Cluster) 2021/2022 by the Faculty of Medicine and Health Sciences UPM and Best editor Award 2021 for the Medical Journal of Malaysia by the Malaysian Medical Association.





Suriaraj Karppaya

Urologist
Queen Elizabeth Hospital, Sabah

Dr Suriaraj completed Fellowship Royal College Of Surgeons (Urology) Glasgow March 2021 and is currently working as a urologist in Queen Elizabeth Hospital Sabah. He was one of the candidates of the pioneer batch parallel Urology Training Pathway in Malaysia.

His special interests include Uro-Oncology, Minimally Invasive Surgery, and Endourology.



Teh Khai Yeong

Consultant Urologist and Head of Unit
Urology Unit, Department of Surgery, Hospital Sultanah Bahiyah Alor Setar

Dr Teh is a consultant urologist and head of unit at Hospital Sultanah Bahiyah Alor Setar. He graduated with Master of Surgery from Universiti Malaya in 2015 and then received his fellowship in urology in 2020.



Toh Charng Chee

Consultant Urologist
Hospital Selayang

Dr Toh obtained his MBBS from Manipal Academy of Higher Education, and subsequently Membership Royal College of Surgeons (Ireland) and Master of Surgery (University Malaya Medical College). He is also a certified ATLS Instructor (Royal College of Surgeons) and has a Certificate in Urodynamics (Bristol Urological Institute), FRCS Urology (Glasgow), Fellowship in Minimal Invasive Surgery (Mackay Memorial Hospital), and Fellowship in Renal Transplantation (Medicana International Istanbul).



Vance Koi Yung Chean

Clinical Oncologist
Hospital Wanita & Kanak-kanak Likas, Sabah

Dr Vance received his Master of Clinical Oncology from University of Malaya in 2021. He has been practising as a Clinical Oncologist in the National Cancer Institute, Malaysia and is currently posted to Sabah to serve at the Women and Children Hospital, Likas.





Yogendren Letchumanasamy

Consultant Nuclear Medicine Physician
Subang Jaya Medical Centre (SJMC)

Dr Yogendren is a Consultant Nuclear Medicine Physician currently practicing in Subang Jaya Medical Centre. He received his MBBS from Chittagong and then was conferred Master of Medicine (Nuclear Medicine).



Zool Hilmi bin Awang

Consultant Nuclear Medicine Physician
Thomson Hospital Kota Damansara

Dr Zool Hilmi Bin Awang is a nuclear medicine specialist with expertise in PET-scan, SPECT-CT, PRRT, PSMA therapy, and SIRT. He obtained his MD from the University Hasanuddin in Makassar, Indonesia in 2002 and completed a Master of Medicine in Nuclear Medicine at the University Sains Malaysia in 2013. In 2017, he completed a fellowship in Theranostic Nuclear Medicine (Oncology) in Germany at Bad Berka and Bonn Hospital University under the supervision of Professor Richard P. Baum and Professor Ahmadzadehfar Hojjat. He also completed a fellowship in Nuclear Medicine Therapy at the MD Anderson Cancer Center in Texas, USA in 2019.

Throughout his career, Dr Zool has held various positions in hospitals in Malaysia and has been involved in numerous projects and studies in nuclear medicine. He was the head of the Nuclear Medicine Department at Sarawak General Hospital from 2015 to 2016 and the head of the Nuclear Medicine service in the State of Sarawak until December 2016. He is a member of several professional organizations, including the Malaysian Society of Nuclear Medicine and Molecular Imaging, the Academy of Medicine Malaysia, the World Association of Radiopharmaceutical Therapy, the European Neuroendocrine Tumours Society, and the Malaysian Medical Association. He was also an adjunct Nuclear Medicine Lecturer at the University Sains Malaysia from 2018-2019.



Zulaikha Binti Rozman

Medical Officer
Department of Clinical Oncology, University Malaya Medical Centre

Dr Zulaikha obtained her undergraduate degree, and is now working as a Medical Officer in the Clinical Oncology Unit, University of Malaya Medical Centre.

Redefining the Role of Nephrectomy in the Era of Immunotherapy in Renal Cell Carcinoma

Toh Charng Chee
Selayang Hospital

The role of nephrectomy in the treatment of metastatic renal cell carcinoma (mRCC) in the era of immunotherapy. Cytoreductive nephrectomy is a surgical procedure to remove the kidney, and it has been traditionally used to reduce the bulk of tumour prior to systemic therapy, eliminating the primary tumour as a potential source of immunosuppression or tumour-promoting growth factor. However, its benefits are still under investigation, and the decision on whether to perform it or not depends on various factors, including the patient's condition and the risks of surgical complications and delays in systemic therapy.

The history of the treatment of mRCC in different eras and describes the findings of several clinical trials, including the Southwest Oncology Group (SWOG), European Organisation for Research and Treatment of Cancer (EORTC), CARMENA, SURTIME, and International Metastatic RCC Database Consortium (IMDC) trials. The results indicate that nephrectomy is not appropriate for all patients, but some patients still benefit from an immediate or delayed procedure. Upfront nephrectomy is associated with overall survival benefits in selected patients with mRCC treated with either targeted therapy (TT) or immune checkpoint inhibitors (ICI). However, there are ongoing clinical trials to further investigate the use of nephrectomy in combination with systemic therapy for mRCC.

In conclusion, a multidisciplinary team approach is necessary to decide on the optimal timing of surgery and systemic therapy for mRCC patients, taking into account various factors, such as the symptomatic, tumour burden, complexity of surgery, tolerability of systemic therapy, and host immune factor. The definite answer on the role of nephrectomy in the era of immunotherapy in mRCC is still pending.



Contemporary Role of Metastasis-Directed Therapy in Renal Cell Carcinoma

Shankar Siva
Peter MacCallum Cancer Centre,
Melbourne, Australia

Metastasis directed therapy (MDT) outlines the use of local therapy in advanced disease outside of the standard context of palliation of local symptoms. MDT has historically only involved surgical resection. MDT has several roles; to be used in lieu of systemic therapy in the context of favourable advanced RCC, to address oligoprogressive disease, or potentially consolidate in the oligoresidual setting. Renal cell carcinoma is traditionally considered a radioresistant disease. With the advent of newer technologies facilitating high dose radiation, in the form of stereotactic ablative radiotherapy (SABR or SBRT), a renaissance of the use of radiotherapy in RCC is presently underway. In the immunotherapy era, radiotherapy as MDT may have particular utility

Focal Therapy for Prostate Cancer- HIFU

Peter Royce
Director of Urology, Alfred Health
Senior Consultant Urologic Surgeon at The Alfred and Cabrini hospitals in Melbourne
Adjunct Clinical Associate Professor, Department of Surgery, Monash University.

Focal Therapy for Localised Prostate Cancer is an option using several modalities, including HIFU Ablation

I will present my 15 years' experience with prostate HIFU ablation, including whole gland and focal treatment, including patient selection, treatment planning, oncology and QoL outcomes

Prostate SBRT – A Local Experience

Muthukkumaran Thiagarajan
Clinical Oncologist, Hospital Kuala Lumpur

Hypofractionation in prostate radiotherapy has been an area of great interest due to its radiobiological advantage as well as resource sparing strategy as the oncological outcomes are similar to conventionally fractionated radiotherapy. This talk will explore the journey of implementation of extreme hypofractionation, also known as stereotactic body radiotherapy, for low to intermediate risk prostate cancer patients within the setting of a public hospital.



Evolution of Prostatectomy Techniques

CS Loh
Gleneagles Hospital Kuala Lumpur

Radical Prostatectomy has a history of more than 120 years with early pioneers like Robert Proust and Hugh Hampton Young first demonstrated the safety of perineal prostatectomy. After the discovery of the PSA in the early 1980s, early prostate cancer cases were on the rise and interest in radical surgery for early prostate cancer increased. From the early 1980s, Pat Walsh's technique of anatomic retropubic prostatectomy became almost standard practice for several decades and continues to be practised today. Vallancien & Guilloneau first demonstrated laparoscopic prostatectomy in 2001 and in the same year, Binder published the first robot-assisted prostatectomy. Robot-assisted laparoscopic prostatectomy gradually gained traction over the ensuing 2 decades and the techniques developed by early pioneers like Menon, Abbou and Binder became standard practice and continue to enjoy widespread popularity. Several variations of techniques were introduced to improve functional outcome although the benefits of many of these techniques are difficult to prove. Boccardi later introduced a radically different approach to robotic prostatectomy with significant improvement in urinary continence outcome. This Retzius-sparing approach has a steep learning curve but is slowly gaining traction. The introduction of the Da Vinci SP single port robot spawned newer approaches such as transvesical and transperineal prostatectomy and the next decade or two will see if these newer approaches gain popularity. Robot-assisted prostatectomy is here to stay with several alternative robotic systems already available in the market and several others in development and the cost of robotic prostatectomy can only come down.

Role of SBRT for Oligometastasis

Shankar Siva
Peter MacCallum Cancer Centre,
Melbourne, Australia

SBRT is a non-invasive treatment modality that may be particularly attractive in the context of men with oligometastatic prostate cancer. Several prospective clinical trials have demonstrated safety and efficacy, and randomised trials have demonstrated capacity to prolong time to initiation of ADT and PFS. Studies of SBRT have largely addressed the oligorecurrent setting, but newer trials are now underway addressing the role of consolidation radiotherapy after initiation of systemic therapy in the low volume advanced disease state.

Management of Complications of RALP

Murali Sundram
Consultant Urologist, Sunway Medical Centre

Common surgical complications of robotic prostatectomy are familiar to most surgeons. Less common non surgical complications are mainly related to 3 main factors – lithotomy position, trendelenberg position and pneumoperitoneum. These non surgical complications include nerve injuries, compartment syndrome, rhabdomyolysis, ocular injuries and increased intracerebral pressure. These injuries are also not readily detected by the anaesthetist.

Peripheral nerve injuries accounts for 12-16% of malpractice injury claims in the US. Positional nerve injuries are hard to predict, difficult to prevent and are the responsibility of the entire OT team. In a prospective study of RALP and extended node dissection, the incidence of lower limb compartment syndrome and rhabdomyolysis defined as CPK > 500IU/l was 16%

Positional modifications to mitigate these complications will be discussed. This include reducing the pneumoperitoneal pressure, reducing the Trendelenburg angle, a second surgical time out with flat supine intervention, modified Z position, and supine/split leg position with side docking. Pharmacological strategies to decrease intraocular and intracerebral pressure will be discussed. They include Total intravenous anaesthesia with propofol, concomitant use of dexmetomidine and intraoperative topical ocular medication

Triplet Therapy – Are We Ready?

Vance Koi Yung Chean
Hospital Wanita & Kanak-Kanak,
LIKAS, Sabah

Systemic treatment options for patients with metastatic hormone-sensitive prostate cancer (mHSPC) have evolved dramatically based on clear evidence that treatment intensification at an early stage improves survival and delays progression over androgen deprivation therapy (ADT) alone. Several studies have been published demonstrating a significant survival advantage by combination treatment with standard ADT plus docetaxel or androgen receptor signaling inhibitors (ARSIs) compared to ADT monotherapy.

Two randomized control trials (RCTs), PEACE-1 and ARASENS, recently compared triplet therapy (docetaxel + ARSI + ADT) to docetaxel + ADT and clearly demonstrated better overall survival (OS) with triplet therapy, making triplet therapy a new standard of care for patients with mHSPC, particularly in high-volume and de novo mHSPC. However, we still need to remain cautious in terms of optimal patient and consider the potential toxicity of triplet therapy on quality of life and financial toxicity.

PARP Inhibitor

Fong Chin Heng
Hospital Pulau Pinang

PARP inhibitors is an exciting new treatment option for metastatic prostate cancer with HRR mutations, evidenced by recent trials that showed superiority over standard androgen deprivation therapy alone.

PARP inhibitors work by binding with PARP protein, resulting in PARP trapping and inhibiting SSB repair. Cancer cells with inherent HRR mutations then relies on repair of DSB by NHEJ, leading to genomic instability and eventual cell death.

HRR mutations can be detected via germline and somatic testing, each with their respective indications and recommendations.

Olaparib and Rucaparib are two PARP inhibitors that are listed as recommended treatment options for mCRPC with HRR mutations who previously received AR directd therapies.

This short lecture goes over the fundamental basics of the mode of actions for PARP inhibitors, short overview of genetic testing for prostate cancer, as well as some of the results from recent clinical trials using PARP inhibitors as a treatment modality.

Lutetium PSMA Therapy for mCRPC

Zool Hilmi Awang
Consultant Nuclear Medicine Physician,
Thomson Hospital Kota Damansara

Lu-177-PSMA therapy is a form of targeted radionuclide therapy for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It involves the use of the radioactive isotope Lu-177, which is bound to a molecule called prostate-specific membrane antigen (PSMA) and administered intravenously to the patient. The Lu-177 emits beta particles, which can selectively target and kill cancer cells that express PSMA, while minimizing harm to surrounding healthy tissue. Lu-177-PSMA therapy has been shown to be effective in reducing pain and improving quality of life in patients with mCRPC, and may also extend survival in some cases.

There is some evidence to suggest that the combination of Lu-177-PSMA therapy with chemotherapy may be more effective than either treatment alone in the treatment of metastatic castration-resistant prostate cancer (mCRPC). Combination of Lu-177-PSMA therapy with the chemotherapy agent resulted in a significant improvement in progression-free survival compared to docetaxel alone in patients with mCRPC.

Imaging in UTUC and Its Challenges

Subapriya Suppiah
Universiti Putra Malaysia

Upper Urinary Tract Urothelial Cell Carcinoma (UTUC) can be detected either incidentally or due to symptomatic presentation such as haematuria and flank pain. UTUC can occur concurrently with bladder cancers in 17% of cases. Patients with carcinoma in situ of the bladder, can have the disease ascend and develop into UTUC in 20-25% of the time in a span of 10 years. Conversely, UTUC will descend into the bladder 22%-47% of the time. Up to 21% of UTUC cases may be associated with Lynch Syndrome, which is the most common inherited cancer syndrome. Radiological imaging of UTUC enables the diagnosis and staging of the disease. Although UTUC is morphologically similar to bladder cancer, these two malignancies are phenotypically different. UTUC show more microsatellite instability and hypomethylation than bladder cancer does. UTUC also presents with muscle invasive disease 60% or the time, while bladder cancer presents with muscle invasive disease 15%-20% of the time. This talk will encompass the role of ultrasound, intravenous pyelography, retrograde pyelography, computed tomography urography (CTU), contrast enhanced CT, and magnetic resonance urography in diagnosing and performing local staging of UTUCs. The combination of ureteroscopic biopsy grading, diagnostic imaging findings such as hydronephrosis, and urinary cytology results can aid the decision-making process between radical nephroureterectomy and kidney-sparing therapy. Furthermore, examples will be given of PET/CT imaging that facilitate the detection of distant metastasis. This talk will include sharing of the challenges encountered in performing these imaging modalities and insights on methods to overcome those limitations.

Template Lymph Node Dissection (LND) in Upper Tract Urothelial Cancers (UTUC)

Murali Sundram
Sunway Medical Centre

Lymph node dissection has long been an integral part of the surgical management of tumours because it is the most accurate modality for staging and prognosis, has a therapeutic potential and allows for selection of patients for adjuvant therapy. However there is a discrepancy between guidelines and clinical practise. Conceptually many surgeons believe that lymphatic and hematogenous metastasis occur simultaneously and not sequentially and thus nodal dissection has no survival benefit and at best only confers local control. LND also incurs additional costs and morbidity with uncertain benefit. There are no standardized templates for UTUC and the increasing use of effective perioperative chemotherapy may negate the value of LND as in the management of breast cancer. As a result, many surgeons outside academic centres use their clinical experience in omitting LND in patients in whom they feel are low risk of having nodal disease.

The European guidelines risk stratify UTUC based on risk of progression. All high risk patients are strongly recommended to undergo radical surgery with a template lymph node dissection. There is now level 1 evidence for adjuvant chemo if locally advanced disease (pT3-4 or pN+ve) is confirmed after surgery.

Perioperative Systemic Therapy for UTUC

Ooi Kai Yun
Clinical Oncologist, Sultan Ismail Hospital Johor

Upper tract urothelial carcinoma (UTUC) accounts for approximately 5-10% of all urothelial carcinomas. UTUC is extremely rare hence sometimes decision making for UTUC is extrapolated from larger bladder cancer trial. Prognosis for invasive UTUC is poor despite radical nephroureterectomy, hence the need for perioperative systemic treatment to improve survival. Currently available evidence shows heterogeneous results, perioperative chemotherapy versus surveillance in upper tract urothelial cancer trial (POUT) and other trials involved immune checkpoint inhibitors (Checkmate) will be discussed.

Neoadjuvant and Adjuvant Treatment Strategies in Muscle Invasive Bladder Cancer

Aldrin Jasper Placidus
Hospital Wanita & Kanak-kanak Sabah

Muscle-invasive bladder cancer (MIBC) accounts for 20 – 30% of all bladder cancers. A substantial number of patients with localized MIBC may be completely cured by surgery alone. However, in spite of this potentially curative surgical treatment, some MIBC patients experience locoregional or distant disease recurrence postoperatively. The low survival outcomes in locally advanced MIBC may be due to the systemic occult micro-metastases which cannot be detected by preoperative imaging studies. This suggest that surgery alone may be insufficient to completely control the disease, and that the additional use of systemic therapy should be considered. To improve the survival outcome, the use of perioperative systemic chemotherapy in conjunction with surgery has been intensively investigated, and the advantages of neoadjuvant chemotherapy and adjuvant have been proven in several randomized controlled trials and meta-analyses.

Laparoscopic and Robotic Radical Cystectomy: The Malaysia experience

Noor Ashani Bin Md.Yusoff,
Consultant Urologist, Hospital Kuala Lumpur.

Radical cystectomy with urinary diversion is the the standard of care for localised Muscle invasive bladder cancer (MIBC) or high risk non muscle invasive bladder cancer (NMIBC). This can be accomplished either through open, laparoscopy or robotic assisted laparoscopic surgery with either extra

Radical cystectomy is a very morbid surgery with high rate of complications. Minimally invasive surgery allow the patient to recover faster with shorter hospital length of stay. We will share our local experience regarding laparoscopic and robotic assisted laparoscopic radical cystectomy.

Minimally Invasive Surgery in Advanced Testicular Tumour

Noor Ashani Bin Md.Yusoff,
Consultant Urologist, Hospital Kuala Lumpur.

Retroperitoneal lymph nodes dissection (RPLND) can be used as primary treatment for stage I non-seminomatous germ cell tumour (NSGCT) as well as treatment for post chemotherapy residual masses.

Open RPLND has long been regarded as the standard approached for retroperitoneal lymphadenectomy. However it is associated with significant morbidity. Laparoscopic RPLND has been used to mitigate the morbidity associated with O-RPLND, but it is technically very challenging with a very steep learning curve.

With greater instrument dexterity and visualisation, Robotic assisted laparoscopic RPLND has gained traction and interest in performing RPLND for advanced NSGCT. We will share our local experience in performing robotic assisted laparoscopic RPLND.

Approach to the Long-term Testicular Cancer Survivor

Diana Greenfield
Senior Consultant nurse and MDT Lead for Late Effects
Weston Park Cancer Centre
Sheffield Teaching Hospitals NHS Foundation Trust
England, UK

Given the medical success of cancer treatment for testicular cancer, there is an increasing cohort of long-term survivors. Practice for follow-up varies according to health system but since the risk of recurrence is low, it is increasingly common to discharge from cancer services after a period of uneventful tumour recurrence monitoring. However, there is increasing evidence that a testicular cancer survivor's journey does not end when the oncologist bids farewell. This talk provides an approach to care beyond completion of oncology follow-up: the Sheffield Late Effects Clinic model of care.

Registration Counter	Foyer of Auditorium, Connexion Conference Centre
Operating Hours	4 th March 2023 0730 – 1700 5 th March 2023 0730 – 1200
Welcome and Introduction	Date : 4 th March 2023 Time : 0830 - 0845 Venue : Auditorium, Connexion Conference Centre
Closing Remarks	Date : 5 th March 2023 Time : 1330hrs Venue : Auditorium, Connexion Conference Centre
Powerpoint Presentation	Presentation using personal laptop is not encouraged. Please save your presentation on a USB Drive and load it on to the congress laptop by the AV assistant for identification.

Guidelines for Speakers and Chairpersons

Speakers' Preview Room

The Speakers' Preview Room is located at Foyer of Auditorium, Level 3A, Connexion Conference and Event Centre, Bangsar South, Kuala Lumpur.

Guidelines for Speakers – Scientific Session

Please submit your presentation at least 3 hours in an USB Drive for uploading on the Congress laptop by the AV Assistant prior to your presentation.

Audio-visual testing facilities are available for your testing and viewing. The staff on duty will assist you in testing and installing your presentation materials. Please note that only PowerPoint by Microsoft Office will be available.

Please be present at your session room at least 10 minutes prior to the start of the session.

Guidelines for Chairpersons

Chairpersons are appointed to moderate and conduct each scientific presentation in an orderly and systematic manner as per the schedule.


All questions and answers should be done at the end of each plenary session when all speakers are called to be seated on stage.

EXHIBITION FLOOR PLAN

4 & 5 MARCH 2023

Venue: **Connexion Conference
and Event Centre,
Bangsar South, Malaysia**

SURE
Section of **URO-Oncology Forum**



1	Johnson & Johnson Sdn Bhd
2	DTC Medical Sdn Bhd
3	Merck Sdn Bhd & Pfizer Sdn Bhd
4	Astellas Pharma (M) Sdn Bhd
5	Merck, Sharpe & Dohme (M) Sdn Bhd
6	Ipsen Pharma Singapore Pte Ltd

7	Dr. Reddy's Laboratories Sdn Bhd
8	Amgen Biopharmaceuticals
9	Transmedic Healthcare
10	DCH Auriga (M) Sdn Bhd
11	AstraZeneca Sdn Bhd



Amgen Biopharmaceuticals Malaysia Sdn Bhd

Suite 9.01, Level 9, Menara Summit, Persiaran Kewajipan USJ 1, UEP
47600 Subang Jaya, Selangor, Malaysia.
Tel : +(603) 8601 7163 (office)
Email : pboey@amgen.com

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Our belief — and the core of our strategy — is that innovative, highly differentiated medicines that provide large clinical benefits in addressing serious diseases are medicines that will not only help patients, but also will help reduce the social and economic burden of disease in society today.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology innovator since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.



Astellas Pharma (M) Sdn Bhd

Suite 18.05, Level 18, CentrePoint North Tower, Mid Valley City,
Lingkaran Syed Putra, 59200 Kuala Lumpur
Tel: +(603) 2202 6999 Fax: +(603) 2202 6988 / 6977
Website: www.astellas.com/my/

At Astellas, we are relentless in our pursuit of scientific progress and in identifying unmet medical needs by monitoring the changes in healthcare from multiple perspectives. We are committed to the realization of greater VALUE by patients and healthcare systems around the world. We achieve this by leveraging our strengths to create innovative new drugs and to find solutions that drive patient access to healthcare and better outcomes.





Astrazeneca Sdn Bhd

The Bousteador, Level 12, No. 10, Jalan PJU7/6, Mutiara Damansara
47800 Petaling Jaya, Selangor.
Website : <http://www.astrazeneca.com/>
Email : stephy.lai@astrazeneca.com

AstraZeneca is a global, science-led, patient-focused pharmaceutical company. We are tireless in seeking to realize the potential of what science can do. Our Purpose is to push the boundaries of science to deliver life-changing medicines. We focus on three main therapy areas – Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory – and we are also selectively active in the areas of autoimmunity, neuroscience and infection. To put ourselves in the best position to push the boundaries of science, we seek to leverage our combination of capabilities, which encompass both small molecules and biologics, and include immunotherapies and developing innovative delivery devices that can offer choice to patients. We follow the science and we put patients first. We play to win and do the right thing.



DCH Auriga (Malaysia) Sdn Bhd

(A Dah Chong Hong Company)

Lot 6, Persiaran Perusahaan Seksyen 23, Kawasan Perusahaan Shah Alam,
40300 Shah Alam, Selangor Darul Ehsan, MALAYSIA.
Tel: +(603) 5541 7748 Fax: +(603) 5542 1486

About DCH Auriga Sdn Bhd

DCH Auriga is an Asian-based integrated market management provider that offers distribution solutions exclusively to the healthcare industry. Formerly LF Asia, we have been building on more than 50 years of service, a well-established network and a new position within Dah Chong Hong Holdings and CITIC Pacific family.

The name “Auriga” is inspired by a constellation known in both the Western and Eastern traditions as ‘the charioteer’. It symbolises our commitment to help our principals navigate market complexities as they explore new opportunities. Auriga represents our mission of stewardship, expansion and growth.



**Dr. Reddy's Laboratories Malaysia Sdn Bhd** (1238154-X)

Unit 10-06, Level 10, Menara MBMR, No. 1, Jalan Syed Putra,
58000 Kuala Lumpur, Malaysia.
Mobile : +(6012) 399 7019
E-mail : wee.sun@drreddys.com
Website : www.drreddys.com

Who We Are

'Good Health' is always our goal. We see medicines not just as molecules, but as means to help patients regain their health. As a leader in the pharmaceutical industry, we realize our unique role; we have the ethical and moral imperative to ensure good health can be delivered to those who need it, and to promote wellness among them. 'Can't Wait' reflects our commitment to act with speed to find innovative solutions that address the unmet needs of patients, and to accelerate access to much-needed medicines for people around the world.

Our Generic Formulations business addresses this urgent need by offering more than 550 high-quality generic versions of expensive innovator medicines—at a fraction of the cost—in over 66 countries around the world.

Generic Formulations, including tablets, capsules, injectable, and topical creams, is the largest part of our business portfolio, making products across the major therapeutic areas of gastrointestinal ailments, cardiovascular disease, pain management, oncology, haematology, anti-infective, paediatrics and dermatology. We have 6 biosimilar products in the market leading pipeline in oncology and autoimmune disease. Active Pharmaceutical ingredients (API) is one of our core businesses. We partner with several leading generic formulation companies in bringing their molecules first to the market. Our API development efforts enable our own generics business to be cost competitive and get to market faster. In our proprietary products business, we focus on development of differentiated formulations for global markets. The aim is to improve the patient's holistic experience with our medicine so as to improve efficacy, ease of use and the resolution of unmet patient needs.





DTG MEDICAL SDN BHD

Unit 27-8, Menara One Mont Kiara, Jalan Kiara,
Mont Kiara, 50480 Kuala Lumpur, Malaysia
Tel : +(603) 5888 9580
Email : customers.my@devicetechnologies.asia

Since 1992, Device Technologies has been dedicated to improving patients' lives through leading edge technology and services.

Successfully supplying hospitals and healthcare professionals with the finest medical solutions for their patients, Device Technologies continues to grow, with over 200 trusted brands and 850 highly skilled staff Australia and New Zealand-wide. Since 2019, Device Technologies has expanded its footprint into Asia, establishing offices in Singapore, Malaysia, Thailand, Vietnam, Philippines, and Hong Kong with over 50 employees across the region.

Leading the way in the medical technology field, Device Technologies provides the highest calibre of medical supplies with innovation and client care at the core of its values. All products distributed by Device Technologies are compliant with quality regulatory requirements, with in-servicing and ongoing support provided as part of the trusted partnership between Device Technologies staff and healthcare professionals.

Device Technologies is proud to work with Intuitive to bring their high-quality robotic-assisted surgical systems and training for healthcare professionals to the Asian markets since 2019.



Ipsen Pharma Singapore Pte Ltd

#10-03, 20 Anson Road, Twenty Anson, 079912 Singapore.
Tel : +(65) 6850 0700

Ipsen is a global biopharmaceutical group dedicated to improving lives through innovative medicines in Oncology, Neuroscience and Rare Diseases. In addition, we have a well-established and successful Consumer Healthcare business. We are committed to discovering new solutions for targeting debilitating diseases and improving the quality of life for patients.





Johnson & Johnson Sdn Bhd (3718-D)

Level 8, The Pinnacle, Persiaran Lagoon, Bandar Sunway,
46150 Petaling Jaya, Selangor Darul Ehsan, Malaysia
Tel: +(603) 7661 4500 Fax: +(603) 7610 0519

At Johnson & Johnson, we blend heart, science and ingenuity to profoundly change the trajectory of health for humanity. We aspire to positively impact patients, consumers and all others we serve with our life-saving medicines, products and devices, as well as the health of our employees, our communities and the planet.

Incorporated in 1960 in Malaysia, Johnson & Johnson Sdn Bhd has a range of diversified offers, ranging from consumer healthcare and medicines to medical devices, to advance the health and well-being of people around the world.

Created in 1943, Our Credo is the cornerstone of Johnson & Johnson's beliefs and outlines a common set of values that unify our diverse businesses





Merck Sdn Bhd

Level 3, Menara Sunway Annexe, Jalan Lagoon Timur,
Bandar Sunway, 46150 Petaling Jaya, Selangor D. E., Malaysia.
Tel : +(603) 7494 3688
Website : www.merckgroup.com/en

At Merck Healthcare, we're on a mission to help patients. Our purpose 'As One for Patients' motivates us to always give our best and continuously improve our efforts. We understand that every decision and contribution we make has an impact on the lives of patients and their caregivers. One of our key therapeutic area is Oncology, which drives our focus on unleashing the full potential of some of the most promising mechanisms in cancer research to transform the standard of care for challenging cancers. In **Fertility**, we believe that everyone should have the opportunity to become a parent. This is why we are dedicated to helping those who wish to have a baby. **Cardiovascular, Metabolism & Endocrinology** brings a better health to every single cardiometabolic and endocrine patient, helping them to live their life to its full potential. Last but not least, we have a long-standing legacy in **Neurology and Immunology** including more than 20 years of experience in Multiple Sclerosis (MS) and are committed to people living with neuroinflammatory diseases by focusing on finding solutions addressing unmet medical needs.



Pfizer Malaysia

General Inquiries
Tel : +(603) 2281 6000
Fax : +(603) 2281 6388

Pfizer: Breakthroughs That Change Patients' Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. To learn more, please visit us on <http://www.Pfizer.com.my> and like us on Facebook at Facebook.com/PfizerMY.



Merck Sharp & Dohme (Malaysia) Sdn Bhd

B-22-1 & B-22-2, The Ascent Paradigm, No 1, Jalan SS7/26A, Kelana Jaya,
47301 Petaling Jaya, Selangor, Malaysia
Tel : +(603) 7499 1600 Mobile : +(6012) 692 7957
Website : www.msd-malaysia.com

About MSD

For over 130 years, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases in pursuit of our mission to save and improve lives. MSD is a trade name of Merck & Co., Inc., with headquarters in Rahway, N.J., U.S.A. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to prevent and treat diseases that threaten people and animals — including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases — as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit www.msd-malaysia.com and connect with us on Twitter, LinkedIn and YouTube.



Transmedic Healthcare Sdn Bhd

B4-1-1, Solaris Dutamas, No 1, Jalan Dutamas 1, 50480 Kuala Lumpur, Malaysia.
Tel: +(603) 6205 3888 Fax: +(603) 6205 4062
Email : enquiries@transmedicgroup.com
Website : www.transmedicgroup.com

Transmedic was founded in 1980 with the aim of becoming the top specialist in the advanced medical technology arena in Southeast Asia. Headquartered in Singapore, we have since grown our presence in 7 countries and have a staff of 506 people.

Conference Secretariat

Malaysian Urological Association

Unit 1.4 (Suite 2), Level 1, Enterprise 3B,
Jalan Inovasi 1, Technology Park Malaysia
(TPM), Lebuhraya Puchong - Sungei Besi,
Bukit Jalil 57000 Kuala Lumpur,
Wilayah Persekutuan
Website: www.mua.my
Email: maluroassociation@gmail.com

Conference Venue

Connexion Conference and Event Centre

7, Jalan Kerinchi, Bangsar South,
59200 Bangsar South City,
Wilayah Persekutuan Kuala Lumpur

REGISTRATION FEES for Section of Uro-Oncology Forum (SURF) 2023

Category	Before 15 Feb 2023	After 15 Feb 2023
Full Delegate Registration	RM 500	RM 650
Medical Officer, Scientist & Non clinician	RM 380	RM 450
International Delegates	USD 250	USD 300

* The above rate inclusive the GST 6%. The Malaysian government officially implemented the Goods & Services Tax (GST) on 1 April 2015. Hence effective from this date, a 6% GST will be included into the registration fees. You may obtain further information on GST from the Royal Malaysian Customs Department website at www.gst.customs.gov.my.

Registration Form

Please return the completed Form to the Secretariat with appropriate fees as early as possible to ensure receipt of the Conference bag and the complete set of conference materials upon checking in at the Conference Registration Desk. Photocopies of the form may be used.

Payment Details

Name of the Account:
Malaysian Urological Association

Account Number: 514075606138

Bank Address :
Malayan Banking Berhad,
Lot AG 1-2 & AG 9-10, Block A,
Plaza Pekeliling, No. 2, Jalan Tun Razak,
50500 Kuala Lumpur

Entitlements

Full registrants will be entitled to:

- Admission to all lectures, abstract sessions and symposiums
- Conference bags and materials
- Name badge and Conference bag
- Admission to the exhibition areas
- Coffee/Tea
- Meals

SCIENTIFIC SESSIONS

Plenary session

Date: 4th March 2023
Venue: Auditorium, Connexion
Conference Centre
Time: 0800 – 2030

Date: 5th March 2023
Venue: Auditorium, Connexion
Conference Centre
Time: 0800 – 1330

Insurance and Liability

The Organising Committee will not be liable for personal accidents, loss or damage to private property of participants during the conference. Participants should make own arrangements with respect to personal insurance.

Conference Website

Regularly updated information on registration, hotel reservation and scientific programme are available online at www.mua.my

Conference Language

The Official language of the Conference will be English.

Certificate of Attendance

A certificate of attendance will be issued to all delegates.

Letter of Invitation

Upon request, the Organising Committee will issue a letter of invitation. The sole purpose of the letter is to facilitate the delegate's travel and visa arrangements. The invitation does not imply provision of financial support. Letters of invitation may be requested by individuals from the Conference Secretariat by email : maluroassociation@gmail.com.

DISCLAIMER

Whilst every attempt will be made to ensure that all aspects of the Conference published in this announcement will take place as scheduled, the Organising Committee assumes no responsibility should any of these fail to materialize for any reason.



Acknowledgements

**The Organising Committee of the
Section of Uro-Oncology Forum 2023 expresses
its grateful thanks to the following for
their contribution and support for the Conference.**

Amgen Biopharmaceuticals Malaysia Sdn Bhd

Astellas Pharma (M) Sdn Bhd

AstraZeneca Sdn Bhd

DCH Auriga (Malaysia) Sdn Bhd

Dr. Reddy's Laboratories Malaysia Sdn Bhd

DTG Medical Sdn Bhd

Ipsen Pharma Singapore Pte Ltd

Johnson & Johnson Sdn Bhd

Merck Sdn Bhd & Pfizer Malaysia

Merck, Sharpe & Dohme (M) Sdn Bhd

Transmedic Healthcare Sdn Bhd

Thank You